A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5946-5951

  Ting, Lillian S L ^a   Praestgaard, Jens ^b   Grunenberg, Nicole ^c,d   Yang, Jenny C ^a,e   Leeds, Jennifer A ^a   Pertel, Peter ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Charles River Clinical Services Northwest Inc   (United States)

^d USA   (United States)

^e Gilead   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ELONGATION FACTOR TU; LFF 571; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG FECES LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EYE DISEASE; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL PAIN; HEADACHE; HUMAN; HUMAN EXPERIMENT; LACERATION; LIPID DIET; MALE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; THIAZOLES;

EID: 84868024327     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00867-12     Document Type: Article

References (18)

1. Ananthakrishnan AN. 2011. Clostridium difficile infection: epidemiology, risk factors and management. Nat. Rev. Gastroenterol. Hepatol. 8:17-26.
2. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 56:2493-2503.
3. Cornely OA, et al. 2012. Fidaxomicin versus vancomycin for infection withClostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12:281-289.
4. Deng G, et al. 2011. Investigation of mode of binding of elongation factor Tu inhibitor LFF571, abstr F1-1859. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
5. Dzink-Fox J, et al. 2011. Antimicrobial activity of the novel elongation factor Tu inhibitor, LFF571, abstr F1-1346. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
6. Hecht D, Osmolski J, Gerding D. 2012. Activity of LFF571 against 103 clinical isolates of C. difficile, abstr P-1440. Abstr. 22nd European Society of Clinical Microbiology and Infectious Diseases, London, United Kingdom.
7. Heinlen L, Ballard JD. 2010. Clostridium difficile infection. Am. J. Med. Sci. 340:247-252.
8. Johnson S. 2009. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J. Infect. 58:403-410.
9. Kelly CP, LaMont JT. 2008. Clostridium difficile - more difficult than ever. N. Engl. J. Med. 359:1932-1940.
10. LaMarche MJ, et al. 2012. Discovery of LFF571: an investigational agent for Clostridium difficile infection. J. Med. Chem. 55:2376-2387.
11. Leeds JA, Sachdeva M, Mullin S, Dzink-Fox J, LaMarche MJ. 2012. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob. Agents Chemother. 56:4463-4465.
12. Lewis SJ, Heaton KW. 1997. Stool form scale as auseful guide to intestinal transit time. Scand. J. Gastroenterol. 32:920-924.
13. Loo VG, et al. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
14. Louie TJ, et al. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
15. McDonald LC, et al. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
16. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7:526-536.
17. Trzasko A, Leeds JA, Praestgaard J, LaMarche MJ, McKenney D. 2012. The efficacy of LFF571 in the hamster model of Clostridium difficile infection. Antimicrob. Agents Chemother. 56:4459-4462.
18. U. S. Department of Health and Human Services. 2002. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Rockville, MD.